Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant and vandetanib in advanced aromatase inhibitor-resistant breast cancer
ISRCTN13663157Phase 2Completed
- Sponsor
- Velindre University NHS Trust
- Start
- Apr 2015
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Fulvestrant + vandetanib with Fulvestrant + placebo (2 arms). Primary endpoint: Progression-free survival. Started Apr 2015; status: completed.
02
Drugs
fulvestrantvandetanib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN13663157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN13663157.